Acute kidney injury and mortality in coronavirus disease 2019: results from a cohort study of 1,280 patients
Background The development of acute kidney injury (AKI) in patients with coronavirus disease 2019 (COVID-19) is associated with a high risk of death. Published data demonstrate the possibility of severe kidney injury in patients suffering from COVID-19. However, these data are still controversial. Methods A total of 1,280 patients with a proven diagnosis of COVID-19 were included in our study. COVID-19 was confirmed in all patients using reverse transcriptase polymerase chain reaction test of a nasopharyngeal swab, and based on the typical computed tomography findings. Demographic data, underlying comorbidities, and laboratory blood tests were assessed. We assessed the incidence of AKI and its associated mortality defined by survival status at discharge. Results Proteinuria was identified with 648 patients (50.6%) with COVID-19. AKI was identified in 371 patients (29.0%). Ten of these patients (2.7%) required dialysis. The risk factors for AKI included age of < 65 years, augmentation of C-reactive protein, ferritin and an increase in values of activated partial thromboplastin time. Overall, 162 of the 1,280 hospitalized patients (12.7%) and 111 of the 371 patients (29.9%) with AKI did not survive. The hazard ratio (HR) for mortality was 3.96 (95% confidence interval, 2.83–5.54) for patients with AKI vs. no AKI. Conclusion AKI was a relatively common finding among patients with COVID-19. The risk factors for AKI in COVID-19 included old age, the inflammatory response, the severity of lung involvement, and disseminated intravascular coagulation. These same factors, in addition to arterial hypertension, were found to increase the risk of mortality..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Kidney Research and Clinical Practice - 40(2021), 2, Seite 241-249 |
| Sprache: |
Englisch ; Koreanisch |
|---|
| Beteiligte Personen: |
Natalia Chebotareva [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Acute kidney injury |
|---|
| doi: |
10.23876/j.krcp.20.128 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ003636356 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ003636356 | ||
| 003 | DE-627 | ||
| 005 | 20230501174843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23876/j.krcp.20.128 |2 doi | |
| 035 | |a (DE-627)DOAJ003636356 | ||
| 035 | |a (DE-599)DOAJ17e5987bdca54a1b9b397191c0aebee4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a kor | ||
| 050 | 0 | |a RC31-1245 | |
| 050 | 0 | |a RC581-951 | |
| 100 | 0 | |a Natalia Chebotareva |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acute kidney injury and mortality in coronavirus disease 2019: results from a cohort study of 1,280 patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background The development of acute kidney injury (AKI) in patients with coronavirus disease 2019 (COVID-19) is associated with a high risk of death. Published data demonstrate the possibility of severe kidney injury in patients suffering from COVID-19. However, these data are still controversial. Methods A total of 1,280 patients with a proven diagnosis of COVID-19 were included in our study. COVID-19 was confirmed in all patients using reverse transcriptase polymerase chain reaction test of a nasopharyngeal swab, and based on the typical computed tomography findings. Demographic data, underlying comorbidities, and laboratory blood tests were assessed. We assessed the incidence of AKI and its associated mortality defined by survival status at discharge. Results Proteinuria was identified with 648 patients (50.6%) with COVID-19. AKI was identified in 371 patients (29.0%). Ten of these patients (2.7%) required dialysis. The risk factors for AKI included age of < 65 years, augmentation of C-reactive protein, ferritin and an increase in values of activated partial thromboplastin time. Overall, 162 of the 1,280 hospitalized patients (12.7%) and 111 of the 371 patients (29.9%) with AKI did not survive. The hazard ratio (HR) for mortality was 3.96 (95% confidence interval, 2.83–5.54) for patients with AKI vs. no AKI. Conclusion AKI was a relatively common finding among patients with COVID-19. The risk factors for AKI in COVID-19 included old age, the inflammatory response, the severity of lung involvement, and disseminated intravascular coagulation. These same factors, in addition to arterial hypertension, were found to increase the risk of mortality. | ||
| 650 | 4 | |a acute kidney injury | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a hematuria | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a proteinuria | |
| 653 | 0 | |a Internal medicine | |
| 653 | 0 | |a Specialties of internal medicine | |
| 700 | 0 | |a Svetlana Berns |e verfasserin |4 aut | |
| 700 | 0 | |a Angelina Berns |e verfasserin |4 aut | |
| 700 | 0 | |a Tatyana Androsova |e verfasserin |4 aut | |
| 700 | 0 | |a Marina Lebedeva |e verfasserin |4 aut | |
| 700 | 0 | |a Sergey Moiseev |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Kidney Research and Clinical Practice |d The Korean Society of Nephrology, 2018 |g 40(2021), 2, Seite 241-249 |w (DE-627)DOAJ000113328 |x 22119140 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2021 |g number:2 |g pages:241-249 |
| 856 | 4 | 0 | |u https://doi.org/10.23876/j.krcp.20.128 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/17e5987bdca54a1b9b397191c0aebee4 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.krcp-ksn.org/upload/pdf/j-krcp-20-128.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2211-9132 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2211-9140 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2021 |e 2 |h 241-249 | ||